Tandem Diabetes Care Appoints New Executive Vice President of Strategy and Corporate Development
January 09 2020 - 4:15PM
Business Wire
Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin
delivery and diabetes technology company, today announced the
appointment of Elizabeth Gasser as its new Executive Vice
President, Strategy and Corporate Development. Gasser will lead all
activities related to evolving and implementing the Company’s
long-term strategic direction in alignment with its mission to
improve the lives of people with diabetes.
“Liz has been an instrumental consultant in recent months,
providing insights to help shape and define our longer-term
strategic business plan, which positions us to lead in insulin
therapy management by building a robust ecosystem and portfolio of
data-driven products and services,” said John Sheridan, president
and CEO of Tandem Diabetes Care. “We are confident in her ability
to lead in the implementation of these strategies as part of the
executive management team and help drive Tandem’s continued
success.”
“Tandem’s strategic plan focuses on providing the world’s best
insulin delivery systems, building relationships and expanding the
value we provide our customers, healthcare providers and payors,
and using data in new ways to deliver revolutionary insights and
experiences,” said Gasser. “There’s meaningful, long-term
opportunity for Tandem and I look forward to contributing in my new
role.”
Before becoming an independent advisor in 2017, Gasser led the
corporate strategy function at Qualcomm Incorporated, working with
the Executive Team and general managers of its various lines of
business. During her 11 years at Qualcomm, she also led strategy
and corporate development for its emerging business portfolio and
the Qualcomm Internet Services division. Prior to Qualcomm, Gasser
spent five years at Openwave Systems, the world’s leading mobile
browser provider at the time, where she held strategy, product and
market research roles. Before Openwave, she worked as a strategy
consultant in both London and San Francisco. Gasser holds a BA and
MA in Economics from Cambridge University, UK. She also serves as
the Board Chair for Athena, a non-profit organization focused on
professional advancement for women in STEM fields.
About Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc. (www.tandemdiabetes.com) is a medical
device company dedicated to improving the lives of people with
diabetes through relentless innovation and revolutionary customer
experience. The Company takes an innovative, user-centric approach
to the design, development and commercialization of products for
people with diabetes who use insulin. Tandem manufactures and sells
the t:slim X2 insulin pump with Control-IQ technology. The t:slim
X2 pump is capable of remote feature updates using a personal
computer. Tandem is based in San Diego, California.
Follow Tandem Diabetes Care on Twitter @tandemdiabetes, use
#tslimX2 and $TNDM.
Follow Tandem Diabetes Care on Facebook at
www.facebook.com/TandemDiabetes. Follow Tandem Diabetes Care on
LinkedIn at www.linkedin.com/company/TandemDiabetes.
Tandem Diabetes Care is a registered trademark, and t:slim X2
and Control-IQ are trademarks of Tandem Diabetes Care, Inc. All
other third-party marks are the property of their respective
owners.
Forward Looking Statement
This press release contains “forward-looking statements” within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, that concern matters that involve risks and uncertainties
that could cause actual results to differ materially from those
anticipated or projected in the forward-looking statements. These
forward-looking statements relate to, among other things, the
anticipated future growth of the Company and the Company’s
abilities to define and implement its longer-term strategic
business plan. These statements are subject to numerous risks and
uncertainties, including our ability to obtain regulatory approval
for new products and products under development and the timing of
any such approvals; market acceptance of the Company’s existing
products and products under development by physicians and people
with diabetes; the Company’s ability to meet increasing operational
and infrastructure requirements from higher customer interest and a
larger base of existing customers; as well as other risks
identified in our most recent Annual Report on Form 10-K and
Quarterly Reports on Form 10-Q, and other documents that we file
with the Securities and Exchange Commission. Readers are cautioned
not to place undue reliance on these forward-looking statements,
which speak only as of the date of this release. Tandem undertakes
no obligation to update or review any forward-looking statement in
this press release because of new information, future events or
other factors.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200109005724/en/
Media: Steve Sabicer, 714-907-6264, ssabicer@thesabicergroup.com
Investors: Susan Morrison, 858-366-6900 x7005,
IR@tandemdiabetes.com
Tandem Diabetes Care (NASDAQ:TNDM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tandem Diabetes Care (NASDAQ:TNDM)
Historical Stock Chart
From Apr 2023 to Apr 2024